NCT04551963View on ClinicalTrials.gov

Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 15, 2020

Primary Completion Date

February 21, 2022

Study Completion Date

February 21, 2022

Conditions
B-cell Malignancies
Interventions
DRUG

Zanubrutinib

Capsules administered at a dose and frequency as specified in the treatment arm

DRUG

Fluconazole

Capsules administered at a dose and frequency as specified in the treatment arm

DRUG

Diltiazem

Capsules administered at a dose and frequency as specified in the treatment arm

DRUG

Voriconazole

Capsules administered at a dose and frequency as specified in the treatment arm

DRUG

Clarithromycin

Capsules administered at a dose and frequency as specified in the treatment arm

Trial Locations (7)

2139

Concord Repatriation General Hospital, Concord

3168

Monash Health, Clayton

3199

Peninsula Private Hospital, Frankston

4224

John Flynn Private Hospital, Tugun

5000

Royal Adelaide Hospital, Adelaide

5042

Flinders Medical Centre, Bedford PK

6009

Linear Clinical Research, Nedlands

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY